ReviewClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2025
Allergen Immunotherapy for the Prevention and Treatment of Asthma.
Review in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06027073 (Adding Biological Therapy to Asthmatic Patients on Allergen Immunotherapy to House Dust Mites), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Adding Biological Therapy to Asthmatic Patients on Allergen Immunotherapy to House Dust Mites
Who cites it
14 citing papers in PubMed.
- Review
- Protective role of lactate in allergic airway inflammation: mitigation of inflammatory injury, epithelial barrier integrity restoration, and gut-lung axis involvement.Respiratory research · 2026Article
- Subcutaneous immunotherapy-induced IgG1 suppresses allergic airway inflammation through FcγRIIb-mediated inhibition of group 2 innate lymphoid cell proliferation.The World Allergy Organization journal · 2026Article
- Observational
- Ameliorating Effects ofAntioxidants (Basel, Switzerland) · 2026Article
- Allergy to Cats: Current Perspectives and Therapeutic Options.Clinical and translational allergy · 2026Review
- Article
- Occupational Allergy to Rat and Mouse in Research Laboratories.Current allergy and asthma reports · 2026Review
- Persistence and Reasons for Discontinuation of Subcutaneous Immunotherapy in Children with Dust Mite Allergy: A Real-World Cohort from Hangzhou, China.Journal of asthma and allergy · 2026Article
- Assessment of knowledge on self-management and level of asthma control among patients attending a tertiary care center in Nepal: A cross-sectional study.PLOS global public health · 2026Article
- Allergen immunotherapy for the control of moderate to severe allergic asthma: an evidence-based conjoint analysis to define candidate patient profiles in Spain and Portugal.Frontiers in allergy · 2025Article
- Allergen characterization in childhood asthma: a retrospective cohort study in China.Frontiers in public health · 2025Article
- Real-world retrospective study on the efficacy and safety of anti-IgE therapy combined with rush immunotherapy in allergic asthma.Frontiers in allergy · 2025Article
- Safety and Effectiveness of Allergen Immunotherapy in Patients with Severe Allergic Asthma.Journal of asthma and allergy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Allergic asthma is the predominant phenotype among asthmatics. Although conventional pharmacotherapy is a central component in the management of asthma, it does not enable control of asthma symptoms in all patients. In recent decades, some uncontrolled asthmatic patients, especially those with allergic asthma, have benefited from biological therapies. However, biologics do not address all the unmet needs left by conventional pharmacotherapy. Furthermore, it is noteworthy that neither conventional pharmacotherapy nor biological therapies have disease-modifying properties. In this context, allergen immunotherapy (AIT) represents an indispensable component of the therapeutic arsenal against allergic asthma, due to its disease-modifying immunological effects. In this review article, funded by an AIT manufacturer, we find clinical trials support AIT as the only treatment option able both to improve allergic asthma symptoms and to prevent the onset and worsening of the condition. For patients with severe asthma or other safety concerns, the combination of AIT and biologics offers very promising new treatment modalities for the management of allergic asthma. Trial Registration: clinicaltrials.gov identifier: NCT06027073.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.